Revaccination of healthy nonresponders with hepatitis B vaccine and prediction of seroprotection response

Vaccine. 2003 Mar 7;21(11-12):1174-9. doi: 10.1016/s0264-410x(02)00626-6.

Abstract

Sixty healthy nonresponders were randomized to receive intramuscular (IM) high dose hepatitis B virus (HBV) vaccine versus IM standard dose HBV vaccine plus granulocyte-macrophage colony-stimulating factor (GM-CSF) at 0-2 months. Antibody to hepatitis B surface antigen was measured 1 month after each dose and 3 months after the last dose. Two regimens were equivalent in eliciting seroprotection in nonresponders. Weight-height index (WHI) <39 and alanine transaminase (ALT) <39 mg/dl predicted which nonresponders would seroconvert. A three-dose regimen of standard dose HBV vaccine plus GM-CSF may be a useful for seroprotection of healthy nonresponders.

Publication types

  • Clinical Trial
  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adjuvants, Immunologic*
  • Adolescent
  • Adult
  • Aged
  • Dose-Response Relationship, Immunologic
  • Female
  • Follow-Up Studies
  • Granulocyte-Macrophage Colony-Stimulating Factor / immunology*
  • Hepatitis B Antibodies / biosynthesis*
  • Hepatitis B Vaccines / administration & dosage
  • Hepatitis B Vaccines / immunology*
  • Humans
  • Immunization, Secondary*
  • Injections, Intramuscular
  • Male
  • Middle Aged
  • Vaccines, Synthetic / administration & dosage
  • Vaccines, Synthetic / immunology*

Substances

  • Adjuvants, Immunologic
  • Hepatitis B Antibodies
  • Hepatitis B Vaccines
  • Recombivax HB
  • Vaccines, Synthetic
  • Granulocyte-Macrophage Colony-Stimulating Factor